Publishers partner with Sermo for "world's largest journal club"

Share this article:

Sermo, the physician online community, formally launched its “Discuss on Sermo” initiative, by which journal publishers provide links to articles and research and can facilitate discussions on them among their readers and Sermo members.

Four publishers, including Nature Publishing Group, the American Medical Association, Advanstar and Wiley-Blackwell, have signed on for the exchange, which offers all parties a means of increasing their exposure to physicians, and more are in talks with Sermo. Alex Frost, VP research initiatives at Sermo, called it “a turnkey solution for those publishers looking to have interactive content.” The feature promises, in turn, to help Sermo build its 60,000-plus-strong membership.

“We recognized early on that 15%-20% of conversations on Sermo related to current news or medical research,” said Frost. “We're being responsive to how physicians are using this platform, so we built tools to facilitate conversation around this.”

The publishers can initiate discussions by placing “Discuss on Sermo” buttons on any article. In doing so, they drive their readers to Sermo, which drives its users back to the title by linking to the text and links separate conversations on it. Publishers can also access anonymized physician discussion data for inclusion in their publications. Sermo members can still link to articles in non-participating journals.

An early run of the feature involved a review published in JAMA indicating excess mortality associated with the use of erythropoiesis-stimulating agents (ESAs), which drew a lot of news coverage. Physicians, however, weren't convinced – three quarters of those participating in a Sermo discussion said they weren't sure the data supported the claim.  

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...